Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

Trial Profile

Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis; Encephalitis virus infections
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top